Immunome (IMNM) News Today $9.53 -0.58 (-5.73%) Closing price 03:59 PM EasternExtended Trading$9.69 +0.16 (+1.67%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Immunome, Inc. (NASDAQ:IMNM) Sees Significant Drop in Short InterestImmunome, Inc. (NASDAQ:IMNM - Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 9,070,000 shares, a drop of 13.9% from the January 15th total of 10,540,000 shares. Based on an average daily volume of 1,000,000 shares, the days-to-cover ratio is currently 9.1 days. Currently, 13.0% of the shares of the stock are sold short.February 17, 2025 | marketbeat.comThree Bridge Wealth Advisors LLC Buys New Position in Immunome, Inc. (NASDAQ:IMNM)Three Bridge Wealth Advisors LLC purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 27,615 shares of the company's stock, valued at approximately $293,000. OtherFebruary 13, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Stock Price Down 6.7% - Here's What HappenedImmunome (NASDAQ:IMNM) Stock Price Down 6.7% - Here's WhyFebruary 11, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for Immunome Q1 Earnings?February 11, 2025 | americanbankingnews.comImmunome (NASDAQ:IMNM) Stock Price Up 11.7% - Here's What HappenedImmunome (NASDAQ:IMNM) Shares Up 11.7% - Still a Buy?February 10, 2025 | marketbeat.comQ1 Earnings Forecast for Immunome Issued By Leerink PartnrsImmunome, Inc. (NASDAQ:IMNM - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Immunome in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.94) for the quarFebruary 10, 2025 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 6, 2025 | businesswire.comInsider Stock Buying Reaches US$2.82m On ImmunomeFebruary 4, 2025 | uk.finance.yahoo.comImmunome (NASDAQ:IMNM) Shares Gap Up After Insider Buying ActivityImmunome (NASDAQ:IMNM) Shares Gap Up After Insider Buying ActivityFebruary 4, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) CEO Purchases $1,162,500.00 in StockFebruary 4, 2025 | insidertrades.comShort Interest in Immunome, Inc. (NASDAQ:IMNM) Grows By 12.2%Immunome, Inc. (NASDAQ:IMNM - Get Free Report) was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 9,870,000 shares, a growth of 12.2% from the December 31st total of 8,800,000 shares. Approximately 19.2% of the shares of the company are sold short. Based on an average daily volume of 787,000 shares, the short-interest ratio is presently 12.5 days.February 4, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall Buys 150,000 SharesImmunome, Inc. (NASDAQ:IMNM - Get Free Report) CEO Clay B. Siegall purchased 150,000 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares of the company's stock, valued at approximately $5,189,679. This trade represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.February 3, 2025 | marketbeat.comScharf Investments LLC Makes New Investment in Immunome, Inc. (NASDAQ:IMNM)Scharf Investments LLC purchased a new stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 44,389 shares of the company's stock, valued aFebruary 1, 2025 | marketbeat.comImmunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesJanuary 31, 2025 | finance.yahoo.comImmunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesJanuary 31, 2025 | businesswire.comImmunome (NASDAQ:IMNM) Trading 7.2% Higher - Still a Buy?Immunome (NASDAQ:IMNM) Stock Price Up 7.2% - What's Next?January 31, 2025 | marketbeat.comImmunome Can Take The Fight To Competitors With VaregacestatJanuary 30, 2025 | seekingalpha.comImmunome (NASDAQ:IMNM) Sees Large Volume Increase - Time to Buy?Immunome (NASDAQ:IMNM) Sees Large Volume Increase - Here's What HappenedJanuary 30, 2025 | marketbeat.comImmunome 19.35M share Spot Secondary priced at $7.75January 30, 2025 | markets.businessinsider.comImmunome announces $125M common stock offeringJanuary 30, 2025 | markets.businessinsider.comImmunome announces $125 million stock offeringJanuary 30, 2025 | msn.comImmunome stock tumbles after public offering pricingJanuary 30, 2025 | msn.comImmunome Announces Pricing of Upsized Public Offering of Common StockJanuary 29, 2025 | businesswire.comImmunome CFO receives relocation package, $400K in bonusesJanuary 24, 2025 | msn.comImmunome CFO Relocation and Compensation Package UnveiledJanuary 23, 2025 | tipranks.comMagnus Financial Group LLC Raises Stake in Immunome, Inc. (NASDAQ:IMNM)Magnus Financial Group LLC boosted its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 107.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 53,536 shares of the company's stock after buying an additional 27,777 shares during the period. MagnuJanuary 23, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Gap Up - Here's What HappenedImmunome (NASDAQ:IMNM) Shares Gap Up - What's Next?January 16, 2025 | marketbeat.comLeerink Partners Sticks to Their Buy Rating for Immunome (IMNM)January 16, 2025 | markets.businessinsider.comImmunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by AnalystsShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been assigned an average rating of "Buy" from the seven research firms that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average tweJanuary 15, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Trading Down 7.1% - Time to Sell?Immunome (NASDAQ:IMNM) Shares Down 7.1% - What's Next?January 14, 2025 | marketbeat.comImmunome (NASDAQ:IMNM) Given "Outperform" Rating at WedbushWedbush reissued an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Monday.January 13, 2025 | marketbeat.comImmunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 13, 2025 | finance.yahoo.comImmunome (NASDAQ:IMNM) Sees Strong Trading Volume - Still a Buy?Immunome (NASDAQ:IMNM) Sees Unusually-High Trading Volume - Here's What HappenedJanuary 13, 2025 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLCBarclays PLC raised its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 125.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,886 shares of the company's stock after buying an aJanuary 13, 2025 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 2, 2025 | businesswire.comImmunome, Inc. (NASDAQ:IMNM) Short Interest Down 10.1% in DecemberImmunome, Inc. (NASDAQ:IMNM - Get Free Report) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 8,800,000 shares, a decline of 10.1% from the November 30th total of 9,790,000 shares. Currently, 17.2% of the shares of the company are sold short. Based on an average daily volume of 788,200 shares, the short-interest ratio is currently 11.2 days.January 1, 2025 | marketbeat.comGeode Capital Management LLC Has $17.66 Million Stake in Immunome, Inc. (NASDAQ:IMNM)Geode Capital Management LLC increased its stake in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 13.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,207,455 shares of the compaDecember 30, 2024 | marketbeat.comImmunome (NASDAQ:IMNM) Shares Down 5.7% - What's Next?Immunome (NASDAQ:IMNM) Stock Price Down 5.7% - Time to Sell?December 27, 2024 | marketbeat.comState Street Corp Sells 176,768 Shares of Immunome, Inc. (NASDAQ:IMNM)State Street Corp decreased its position in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 7.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,187,466 shares of the company's stock after selling 176,768 sharesDecember 22, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from AnalystsShares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been given an average rating of "Buy" by the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price target amoDecember 21, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLPWellington Management Group LLP lifted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM - Free Report) by 137.1% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 140,690 shares of the company's stock after acquiring an additional 81,354 shares duriDecember 19, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Short Interest UpdateImmunome, Inc. (NASDAQ:IMNM - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 9,790,000 shares, a decline of 8.2% from the November 15th total of 10,670,000 shares. Currently, 19.3% of the company's shares are sold short. Based on an average trading volume of 787,600 shares, the days-to-cover ratio is presently 12.4 days.December 16, 2024 | marketbeat.com3 Small-Cap Stocks With Big Growth Potential (IMNM)Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.December 13, 2024 | marketbeat.comImmunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. raised its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 217.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 442,477 shares of the company's stock after purchasing an additional 302,916 shares during the periDecember 12, 2024 | marketbeat.comImmunome: A Recently Acquired Lead Asset And A Small MarketDecember 11, 2024 | seekingalpha.comPoint72 Asset Management L.P. Buys 85,580 Shares of Immunome, Inc. (NASDAQ:IMNM)Point72 Asset Management L.P. increased its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 22.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 470,647 shares of the company's stock after purchasing an additional 85,580 shares during theDecember 9, 2024 | marketbeat.comJanus Henderson Group PLC Has $50.97 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM)Janus Henderson Group PLC raised its position in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 10.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,488,121 shares of the company'December 6, 2024 | marketbeat.comImmunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | businesswire.comImmunome to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 27, 2024 | finance.yahoo.comImmunome Inc.November 26, 2024 | wsj.com Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address IMNM Media Mentions By Week IMNM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMNM News Sentiment▼1.820.60▲Average Medical News Sentiment IMNM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMNM Articles This Week▼13▲IMNM Articles Average Week Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRNX News Today ZLAB News Today DNLI News Today XENE News Today MOR News Today TWST News Today VCEL News Today CPRX News Today MLTX News Today MRUS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMNM) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
